Cancer News and Research

Latest Cancer News and Research

Vitamin D: sunshine, diet and supplements - cancer prevention and therapy

Vitamin D deficiency is common and cancer risk is higher among those individuals with low vitamin D levels, according to an analysis of research which will be presented at a symposium by Donald L.

17 Apr 2007

Brain tumor vaccine shows promise

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

17 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Side-effects of treatment for localized prostate cancer

It seems plausible that prostate cancer (CaP) patients might value health states associated with side-effects of treatment for localized CaP as less detrimental than men with no CaP.

17 Apr 2007

Predicting cancer risk in the long term

Every day, people make assumptions, educated and not, about their risk for developing cancer.

17 Apr 2007

Progen Pharmaceuticals announces positive results in PI-88 trial

Progen Pharmaceuticals Limited has announced the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer.

17 Apr 2007

Komen and AACR address cancer disparities

Uniting the world's oldest and largest scientific organization dedicated to cancer research with the world's largest network of cancer survivors and activists, the American Association for Cancer Research (AACR) and Susan G.

17 Apr 2007

Osprey Pharmaceuticals issued 3 U.S. patents

Osprey Pharmaceuticals Limited has announced that it has been granted three patents by the U.S. Patent Office.

17 Apr 2007

Connection between cancer development and Darwinian evolution explored

Cancer is a natural consequence of human evolution. Our genes have not developed to give us long and happy lives.

17 Apr 2007

Lilly and AACR tackle cancer together

Innovative and collaborative cancer research can be the catalyst to improving patient outcomes.

17 Apr 2007

Researchers induce cell death in leukemia

Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).

17 Apr 2007

Johns Hopkins develops pancreas cancer risk software tool

People with a family history of pancreas cancer now have a way to accurately predict their chance of carrying a gene for hereditary pancreas cancer and their lifetime risk of developing the disease.

17 Apr 2007

High levels of antibodies - low levels of cancer!

Active immunisation can stimulate the body to produce highly efficient IgE antibodies that attack tumours.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Access to dermatologist improves melanoma-related health outcomes

Individuals whose melanoma is diagnosed by a dermatologist may be more likely to have early-stage cancer and to survive five years than those with melanoma diagnosed by a non-dermatologist, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Cortical mapping helps brain tumor removal

In 2006, it was estimated that 18,820 new cases were diagnosed and 12,820 deaths were associated with malignant tumors of the brain and other parts of the central nervous system.

17 Apr 2007